Lisa Horowitz, PhD, MPH (she/her)

Dr. Lisa M. Horowitz is a Pediatric Psychologist/Staff Scientist at the National Institute of Mental Health Intramural Research Program at the National Institutes of Health. She serves as a senior attending with a specialty in pediatric psychology on the Psychiatry Consultation Liaison Service in the Hatfield Clinical Research Center at NIH.

Dr. Horowitz received her doctorate in clinical psychology from George Washington University, completed a Pediatric Health Service Research Fellowship at Harvard Medical School, and obtained a Masters in Public Health at the Harvard School of Public Health.

The major focus of Dr. Horowitz’s research has been in the area of suicide prevention with an emphasis on detection of suicide risk in the medical setting. She is lead PI on five NIMH suicide prevention protocols that involve validating and implementing the Ask Suicide-Screening Questions (ASQ) in the ED, inpatient medical/surgical, and outpatient primary care settings.

Dr. Horowitz is collaborating with hospitals, outpatient pediatric clinics, and school settings around the country, assisting with implementation of suicide risk screening and management of patients who screen positive using the ASQ Toolkit and Youth Suicide Risk Screening Clinical Pathways.

2021 Presentation

Suicide Risk Screening and Management of Patients Who Screen Positive:
From Research to Practice

Healthcare providers can be partners in suicide prevention. This workshop will focus on screening and feasibly managing patients at risk for suicide without overtaxing medical settings.

Presentation Summary:

Over a quarter of all youth deaths and a fifth of all adult deaths in the US are attributable to suicide, a preventable outcome. The majority of those who die by suicide visit a healthcare provider in the months before their death, uniquely positioning healthcare providers to identify those at risk and bridge them to mental health care. However, most healthcare providers do not have effective tools or the training needed to detect and manage patients at risk for suicide. There are many challenges to implementing a suicide risk screening program, such as time, stigma, and most recently the COVID-19 pandemic; yet there are now feasible ways to identify patients at risk for suicide and manage their care without overburdening practice workflows.  Using evidence-based suicide risk screening clinical pathways, we can eliminate barriers and make suicide risk screening programs effective and efficient. Evidence based tools for providers and real world examples of successful ways in which healthcare providers could be partners in suicide prevention will be presented.

Scroll to Top